Norliqva Generic: When Will Generic Amlodipine Be Available?
This page is aggregated from FDA records, court filings and company announcements. Coded and designed by Dr. Brian Staiger, PharmD, BCPS
Updated October 9, 2026 How we build our data
Norliqva Generic at a Glance
Four quick answers from FDA records and our estimate.
- When is the first generic expected? February 2041 About 14.5 years away Why then?
- Has the FDA approved a generic? October 2005 18 companies approved
- When does the last patent end? February 2041 6 patents listed with the FDA
- Can you buy a generic today? Yes 65 companies list one
It already is. A generic amlodipine besylate is listed for sale by 65 companies, so ask your pharmacy whether it can fill your prescription with one.
Why February 2041?
It is when Norliqva’s patents 11,253,474, 11,458,095, 11,723,866, 12,005,141 and 1 more end. They cover the product’s formulation and a way of using it, and once they end, generics can go on sale as soon as the FDA approves them. We rate it toss-up: still unsettled. Just as likely to slip as to hold.
What should I do now?
Ask your pharmacy whether it can fill your prescription with a generic. It may look different from Norliqva, but the active ingredient, strength and form are the same. What a generic means for you
Our month is only an estimate based on available information, so we never name a day.
Norliqva by the Numbers
- Reason
- Patent expiresA patent that protects the brand runs out. After that, approved generics can be sold.
- How sure
- Toss-up Still unsettled. Just as likely to slip as to hold.
- Price competition
- None filed yet No filers on record
- Brand sales
- $5M a yearSmaller seller
- FDA approved 2022 February 2022 FDA Orange Book
- Patents listed 6 last runs to February 2041 FDA Orange Book
- Generics FDA-approved 18 companies, the first approved October 2005 FDA Orange Book
- Pharmacies pay $3.22 per mL NADAC, October 2026
- Medicare Part D spent $1M in 2025, for 324 people CMS Part D Spending by Drug
- Medicaid prescriptions 2,680 in the last four reported quarters, $1.4M CMS Medicaid drug utilization, to Q4 2025
Norliqva’s Road to a Generic
Norliqva has had the market to itself since the FDA approved it in February 2022 (Cmp Development LLC). Its 6 listed patents run to February 2041.
The first generic of Norliqva is expected in February 2041.
Why that month: patents 11,253,474, 11,458,095, 11,723,866, 12,005,141 and 1 more, on the product’s formulation and a way of using it, end then.
Each bar runs from the brand’s approval to the day that protection ends. The green band is our projection for the first generic: a month, never a day, because legal dates move and a generic reaches shelves days to weeks after it is allowed. Sources: FDA Orange Book; the expected month from court records and company announcements.
Norliqva Patents and FDA Protections
Every patent and exclusivity the FDA Orange Book lists for Norliqva’s own applications. A protection running past the expected month does not mean the date is wrong: a settlement or a court ruling can let a generic in before a patent ends, and a patent on one formulation or use does not block every generic.
The one that matters for a generic launch: patents 11,253,474, 11,458,095, 11,723,866, 12,005,141 and 1 more, which end in February 2041, the month the first generic is expected.
| Patent | What it covers | Protects until | Status |
|---|---|---|---|
| 11,253,474 Sets the expected month of generic availability | The product’s formulation; a way of using it (U-3309, U-3310, U-3311) | February 2041 | Active |
| 11,458,095 Sets the expected month of generic availability | The product’s formulation; a way of using it (U-3309, U-3310, U-3311) | February 2041 | Active |
| 11,723,866 Sets the expected month of generic availability | The product’s formulation; a way of using it (U-3309, U-3311, U-3310) | February 2041 | Active |
| 12,005,141 Sets the expected month of generic availability | The product’s formulation; a way of using it (U-3311, U-3309, U-3310) | February 2041 | Active |
| 12,226,528 Sets the expected month of generic availability | The product’s formulation; a way of using it (U-3309, U-3310, U-3311) | February 2041 | Active |
| 12,440,441 | The product’s formulation; a way of using it (U-3309, U-3311, U-3310) | February 2041 | Active |
Source: FDA Orange Book, application 214439. Patent numbers open the patent on Google Patents.
Who Is Lined Up to Make Generic Amlodipine Besylate
Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.
Applied to the FDA
No application count is on record for Norliqva, but the FDA has already approved 18 companies (step 2), and every approval starts with an application.
Approved by the FDA
The FDA has approved generic versions from 18 companies, the first in October 2005. Approved is not the same as on sale: patents, a settlement or the company’s own plans can still hold a launch.
For Sale in Pharmacies
Yes. A generic amlodipine besylate is listed for sale by 65 companies. Ask your pharmacy whether it can fill your prescription with it.
A-S Medication Solutions, ACI Healthcare USA, Inc., American Health Packaging, Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals NY LLC, Aphena Pharma Solutions - Tennessee, LLC and 34 more
| Company | First approved | Strengths | Rated |
|---|---|---|---|
| Corepharma LLC | May 2007 | EQ 2.5MG BASE, EQ 5MG BASE, EQ 10MG BASE | AB |
| Teva Pharmaceuticals USA Inc | June 2007 | EQ 2.5MG BASE, EQ 5MG BASE, EQ 10MG BASE | AB |
| Zydus Pharmaceuticals USA Inc | July 2007 | EQ 2.5MG BASE, EQ 5MG BASE, EQ 10MG BASE | AB |
| Lupin Ltd | July 2007 | EQ 2.5MG BASE, EQ 5MG BASE, EQ 10MG BASE | AB |
| Aurobindo Pharma Ltd | July 2007 | EQ 2.5MG BASE, EQ 5MG BASE, EQ 10MG BASE | AB |
| Chartwell Rx Sciences LLC | July 2007 | EQ 2.5MG BASE, EQ 5MG BASE, EQ 10MG BASE | AB |
| Invagen Pharmaceuticals Inc | August 2007 | EQ 2.5MG BASE, EQ 5MG BASE, EQ 10MG BASE | AB |
| Cipla Ltd | September 2007 | EQ 2.5MG BASE, EQ 5MG BASE, EQ 10MG BASE | AB |
| Epic Pharma LLC | April 2009 | EQ 2.5MG BASE, EQ 5MG BASE, EQ 10MG BASE | AB |
| Alkem Laboratories Ltd | May 2009 | EQ 2.5MG BASE, EQ 5MG BASE, EQ 10MG BASE | AB |
| Orbion Pharmaceuticals Private Ltd | July 2009 | EQ 2.5MG BASE, EQ 5MG BASE, EQ 10MG BASE | AB |
| Oxford Pharmaceuticals LLC | April 2010 | EQ 2.5MG BASE, EQ 5MG BASE, EQ 10MG BASE | AB |
| China Resources Saike Pharmaceutical Co Ltd | April 2011 | EQ 2.5MG BASE, EQ 5MG BASE, EQ 10MG BASE | AB |
| Graviti Pharmaceuticals Inc | April 2012 | EQ 2.5MG BASE, EQ 5MG BASE, EQ 10MG BASE | AB |
| Accord Healthcare Inc | April 2013 | EQ 2.5MG BASE, EQ 5MG BASE, EQ 10MG BASE | AB |
| Unichem Laboratories Ltd | October 2013 | EQ 2.5MG BASE, EQ 5MG BASE, EQ 10MG BASE | AB |
| Puracap Laboratories LLC Dba Blu Pharmaceuticals | July 2016 | EQ 2.5MG BASE, EQ 5MG BASE, EQ 10MG BASE | AB |
| Teva Pharmaceuticals Inc | January 2026 | EQ 2.5MG BASE, EQ 5MG BASE, EQ 10MG BASE | AB |
| Mylan Pharmaceuticals Inc discontinued | October 2005 | EQ 2.5MG BASE, EQ 5MG BASE, EQ 10MG BASE | – |
| Synthon Pharmaceuticals Inc discontinued | June 2007 | EQ 2.5MG BASE, EQ 5MG BASE, EQ 10MG BASE | – |
| Genpharm Inc discontinued | July 2007 | EQ 2.5MG BASE, EQ 5MG BASE, EQ 10MG BASE | – |
| Hikma Pharmaceuticals USA Inc discontinued | July 2007 | EQ 2.5MG BASE, EQ 5MG BASE, EQ 10MG BASE | – |
| Sciegen Pharmaceuticals Inc discontinued | July 2007 | EQ 2.5MG BASE, EQ 5MG BASE, EQ 10MG BASE | – |
| Sun Pharmaceutical Industries Ltd discontinued | July 2007 | EQ 2.5MG BASE, EQ 5MG BASE, EQ 10MG BASE | – |
| Strides Pharma Global Pte Ltd discontinued | July 2007 | EQ 2.5MG BASE, EQ 5MG BASE, EQ 10MG BASE | – |
| Gedeon Richter USA Inc discontinued | July 2007 | EQ 2.5MG BASE, EQ 5MG BASE, EQ 10MG BASE | – |
| Watson Laboratories Inc discontinued | July 2007 | EQ 2.5MG BASE, EQ 5MG BASE, EQ 10MG BASE | – |
| Puracap Pharmaceutical LLC discontinued | September 2007 | EQ 2.5MG BASE, EQ 5MG BASE, EQ 10MG BASE | – |
| Wockhardt Ltd discontinued | September 2007 | EQ 2.5MG BASE, EQ 5MG BASE, EQ 10MG BASE | – |
| Sun Pharmaceutical Industries Inc discontinued | November 2007 | EQ 2.5MG BASE, EQ 5MG BASE, EQ 10MG BASE | – |
| Amneal Pharmaceuticals Ny LLC discontinued | January 2008 | EQ 2.5MG BASE, EQ 5MG BASE, EQ 10MG BASE | – |
| Pharmobedient Consulting LLC discontinued | February 2008 | EQ 2.5MG BASE, EQ 5MG BASE, EQ 10MG BASE | – |
| Torrent Pharmaceuticals Ltd discontinued | September 2008 | EQ 2.5MG BASE, EQ 5MG BASE, EQ 10MG BASE | – |
| Hikma Pharmaceuticals discontinued | April 2011 | EQ 2.5MG BASE, EQ 5MG BASE, EQ 10MG BASE | – |
| Sovereign Pharmaceuticals LLC discontinued | July 2015 | EQ 2.5MG BASE, EQ 5MG BASE, EQ 10MG BASE | – |
| Sunshine Lake Pharma Co Ltd discontinued | May 2018 | EQ 2.5MG BASE, EQ 5MG BASE, EQ 10MG BASE | – |
Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; tentative approvals from Drugs@FDA; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).
Norliqva Price: What Pharmacies Pay and What Generics Usually Do
What Pharmacies Pay for Norliqva 1 mg/mL solution
$3.22 per mL in October 2026.
Hover over or tap anywhere on the chart to see that month’s price.
See the numbers
| Month | Pharmacies paid per mL |
|---|---|
| October 2026 | $3.22 |
| September 2026 | $3.22 |
| August 2026 | $3.22 |
| July 2026 | $3.19 |
| June 2026 | $3.22 |
| May 2026 | $3.21 |
| April 2026 | $3.21 |
| March 2026 | $3.18 |
| February 2026 | $3.23 |
| January 2026 | $3.29 |
NADAC: the national average price retail pharmacies pay to buy the medicine (CMS survey, updated weekly), the last price of each month for one package. It is not what you pay: that depends on your insurance or discount card.
What a Generic Could Cost
How we estimate it. We start from what pharmacies pay for Norliqva today: $3.22 per mL for Norliqva 1 mg/mL solution in October 2026, from the national NADAC survey. Then we apply the FDA’s finding of how far that price usually falls as generic companies join: about 31% with one company, 44% with two, 73% with four and over 95% with six or more (the typical drop for every drug whose first generic came out from 2015 to 2017).
Dollar figures apply FDA’s median drops to the $3.22 pharmacies pay per mL today. An estimate from the pattern, not a price quote: what you pay depends on your insurance or discount card.
Median prices pharmacies paid for the generic (invoice prices), compared with the brand’s price before generic entry, from FDA’s 2019 analysis “Generic Competition and Drug Prices”. At the manufacturer’s price FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker. A typical pattern, not a price quote for this medicine.
What Medicare and Medicaid Spend on Norliqva
Big public spending is part of why generic makers line up for a medicine, and why its first generic matters beyond the pharmacy counter. Figures are before manufacturer rebates, which are confidential.
Medicare Part D Spending
What Medicare drug plans spent on Norliqva, before manufacturer rebates.
- $299.7K
- January to March 2026, the latest CMS has posted
For 185 people, about $765 per prescription fill - $1M
- 2025, the whole year
For 324 people, about $774 per prescription fill
See the numbers
| Period | Spending | People | Per fill |
|---|---|---|---|
| January to March 2026 | $299,703 | 185 | $764.55 |
| 2025 | $1,005,730 | 324 | $774.23 |
Source: CMS Medicare Part D Spending by Drug, matched by the brand name Norliqva only, so no generic is counted in it. What CMS says it is used for: This medication is used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems.
Medicaid Prescriptions by Quarter
2,680 prescriptions in the four quarters to Q4 2025, $1.4M paid.
See the numbers
| Quarter | Prescriptions | Medicaid paid |
|---|---|---|
| Q4 2025 | 708 | $372,738 |
| Q3 2025 | 782 | $399,942 |
| Q2 2025 | 634 | $344,624 |
| Q1 2025 | 556 | $306,124 |
Source: CMS Medicaid State Drug Utilization Data, over Norliqva’s own package codes.
Norliqva Strengths and Forms
| Strength | Form | How it is taken | Approved | Status |
|---|---|---|---|---|
| EQ 1MG BASE/ML | Solution | Oral | February 2022 | Prescription reference product |
Source: FDA Orange Book, Cmp Development LLC. Listed for sale today by CMP Pharma, Inc. (FDA NDC Directory).
Norliqva NDC Codes and Packages
Each Norliqva package sold today has its own NDC, the product number printed on the box and on the pharmacy label. Open one to see that package’s details, what pharmacies pay for it and its patent timeline.
| NDC | Product | Package | Company |
|---|---|---|---|
| 46287-0035-15 | AMLODIPINE 1 mg/mL solution | bottle of 150 mL | CMP Pharma, Inc. |
| 46287-0035-15 | AMLODIPINE 1 mg/mL solution | bottle of 150 mL | CMP Pharma, Inc. |
| 46287-0037-01 | AMLODIPINE 1 mg/mL solution | bottle of 150 mL | CMP Pharma, Inc. |
Source: the FDA NDC Directory, current listings only. Only packages sold under Norliqva’s own FDA approval (NDA 214439) are listed, never a generic. Some codes belong to companies that repackage Norliqva: it is the same medicine in a different package.
What a Generic Norliqva Means for You
Nothing Changes Until It Is in Pharmacies
A generic is listed for sale now, so your pharmacy may already be able to fill your prescription with it.
Your Pharmacy May Switch You Automatically
Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.
It Will Probably Look Different
US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.
Your Insurance May Change Too
Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.
Questions people ask about Norliqva
Is there a generic for Norliqva right now?
Yes. The FDA NDC Directory lists a generic amlodipine besylate from 65 companies. Ask your pharmacy whether it can fill your prescription with it.
When will Norliqva go generic?
It already has. The FDA NDC Directory lists a generic amlodipine besylate from 65 companies, so ask your pharmacy whether it can fill your prescription with one.
Will generic amlodipine besylate be the same as Norliqva?
Yes in the ways that matter: the same active ingredient, strength and form, with proof that it reaches your blood the same way. Inactive ingredients can differ, which is why some people notice a different look or taste.
How much will the generic cost?
Nobody can say for sure before launch. The FDA has already approved 18 companies to make a generic, and how many of them launch decides how far the price falls.
Has the FDA approved a generic Norliqva?
Yes. The FDA Orange Book lists approved generic versions from 18 companies, the first approved in October 2005: Corepharma LLC, Teva Pharmaceuticals USA Inc, Zydus Pharmaceuticals USA Inc, Lupin Ltd and 14 more. Approved is not the same as on sale: patents, a settlement or the company’s own plans can still hold a launch.
When does the Norliqva patent expire?
The FDA Orange Book lists 6 patents for Norliqva; the last runs to February 2041. The one behind the expected month is patents 11,253,474, 11,458,095, 11,723,866, 12,005,141 and 1 more, which end in February 2041. A patent date is not the launch date: settlements and court rulings often bring a generic earlier, and FDA approval or a company’s own plans can make it later. The expected month on this page (February 2041) weighs all of that.
How much does Norliqva cost now?
Pharmacies paid about $3.22 per mL for Norliqva 1 mg/mL solution in October 2026, by the national survey of what pharmacies pay (NADAC). That is the pharmacy’s cost, not your price: what you pay depends on your insurance or discount card.
Changes to This Projection
- First generic expected February 2041 on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.
Every change to the expected month is logged here with the month we saw it.
Also Going Generic
- Tirosint-SolLevothyroxine Sodium2026 to 2027
- PlenvuAscorbic Acid, Polyethylene Glycol 3350, Potassium Chloride, Sodium Ascorbate, Sodium Chloride, and Sodium Sulfate2028 to 2029
- FlolipidSimvastatinFebruary 2030
- BrixadiBuprenorphineJuly 2032
- YorvipathPalopegteriparatide2039 to 2040
- LisrayaBrepocitinib TosylateDuring 2042
About Norliqva
- Generic name amlodipine besylate
- How it is taken By mouth
- Company Cmp Development LLC
- More drugs Brand-name drugs starting with N
- Have a question? A pharmacist answers, free. Ask about Norliqva
Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, Drugs@FDA (tentative approvals), FDA NDC Directory, NADAC (CMS), CMS Medicare Part D Spending by Drug, Medicaid State Drug Utilization Data, FDA, Generic Competition and Drug Prices (2019). Updated October 9, 2026. Information, not medical advice.